Detalles de la búsqueda
1.
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.
Nat Rev Rheumatol;
19(9): 592-602, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37433880
2.
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.
Lupus Sci Med;
10(1)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012059
3.
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN).
Lupus Sci Med;
9(1)2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36007978
4.
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
Ann Rheum Dis;
2022 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35798534
5.
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
J Rheumatol;
49(4): 380-387, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34853089
6.
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
RMD Open;
7(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33568556
7.
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Am J Nephrol;
45(5): 380-388, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28343225
Resultados
1 -
7
de 7
1
Próxima >
>>